Increasing attention has been directed toward the concept of a therapeutic window of opportunity, which frames early PsA as a transitional phase characterized by musculoskeletal symptoms such as arthralgia, dactylitis, and subclinical enthesitis in patients with PsO, often preceding clinically evident arthritis (72), reported that GLP-1RA treatment in PsO patients receiving systemic therapy did not significantly alter the subsequent risk of developing PsA
When Metformin Remains a First-Line Choice Metformin remains the standard initial medication for type 2 diabetes because it is affordable, well-tolerated, has decades of safety data, and addresses insulin resistancethe root driver of many metabolic disorders
This case highlights the need for clinical vigilance in patients with known or incidental diverticular disease receiving GLP-1 based therapies
Semaglutide Treatment Options Semaglutide is administered as a once-weekly injection, typically in the abdomen, thigh, or upper arm
